Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button wuxixdc_info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Webinar

A Novel Conjugation Technology that Generates ADCs with a Narrowly Distributed DAR
A Novel Conjugation Technology that Generates ADCs with a Narrowly Distributed DAR
Jun. 19, 2023

Qirui Fan, Ph.D.

 

Associate Director, New Technology Development & Business Support, WuXi XDC, A WuXi Biologics Subsidiary

 

Conventional conjugation methods result in heterogeneous ADC products due to a wide drug-to-antibody ratio (DAR) distribution. Over the last decade, many site-specific conjugation technologies have been developed to address this issue, yet the improved homogeneity usually comes with a cost and other technical challenges. To address these concerns, WuXi XDC developed the novel WuXiDARx™ technology platform, featuring a myriad of benefits for ADC development and manufacturing. This webinar will outline those key elements that result in ADCs generated with ideal developability characteristics and strong in vitro and in vivo profiles when compared to reference ADCs generated using other conjugation approaches. The enhanced preclinical advantages of the WuXiDARx ADCs may lead to better clinical efficacy and safety and thus far, six ADC molecules generated using one of the WuXiDARx platforms (WuXiDAR4™) have finished large-scale GMP runs and entered phase I clinical trials. Multiple case studies and data comparing the ADC quality attribute profiles of WuXiDARx-generated ADCs will be presented.

 

Discuss This Webinar

To discuss this webinar, please complete the form on the following page to connect with our experts.

Connect with our Experts

Notice:

You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?